Decision making in the management of recurrent head and neck cancer

Head and Neck

Volumn 36, Issue 1, 2014, Pages 144-151

  Ho, Allen S ^a   Kraus, Dennis H ^a   Ganly, Ian ^a   Lee, Nancy Y ^a   Shah, Jatin P ^a   Morris, Luc G T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cancer recurrence; head and neck cancer; quality of life; reirradiation; salvage surgery

Indexed keywords

CETUXIMAB; FLUOROURACIL; PLATINUM;

CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE FREE INTERVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; MEDICAL DECISION MAKING; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

CANCER RECURRENCE; HEAD AND NECK CANCER; QUALITY OF LIFE; REIRRADIATION; SALVAGE SURGERY;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DECISION MAKING; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; QUALITY OF LIFE; RETREATMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 84890434723     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23227     Document Type: Review

References (67)

1. Goodwin WJ Jr,. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000; 110 (3 Pt 2 Suppl 93): 1-18.
2. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
3. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
4. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
5. Agra IM, Carvalho AL, Ulbrich FS, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck 2006; 28: 107-113.
6. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518-5523.
7. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68: 731-740.
8. Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007; 117: 1019-1023.
9. Holsinger FC, Funk E, Roberts DB, Diaz EM Jr,. Conservation laryngeal surgery versus total laryngectomy for radiation failure in laryngeal cancer. Head Neck 2006; 28: 779-784.
10. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
11. Colevas AD,. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2644-2652.
12. Fury MG, Pfister DG,. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2011; 9: 681-689.
13. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
14. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I,. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011; 29: 739-746.
15. Peck BW, Dahlstrom KR, Gan SJ, et al. Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. Head Neck 2012 Jun 19. doi: 10.1002/hed.23033.
16. van der Laan BF, Baris G, Gregor RT, Hilgers FJ, Balm AJ,. Radiation-induced tumours of the head and neck. J Laryngol Otol 1995; 109: 346-349.
17. Amemiya K, Shibuya H, Yoshimura R, Okada N,. The risk of radiation-induced cancer in patients with squamous cell carcinoma of the head and neck and its results of treatment. Br J Radiol 2005; 78: 1028-1033.
18. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A,. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys 1988; 15: 575-579.
19. Zbaren P, Nuyens M, Curschmann J, Stauffer E,. Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas. Head Neck 2007; 29: 26-32.
20. Jones AS, Bin Hanafi Z, Nadapalan V, Roland NJ, Kinsella A, Helliwell TR,. Do positive resection margins after ablative surgery for head and neck cancer adversely affect prognosis? A study of 352 patients with recurrent carcinoma following radiotherapy treated by salvage surgery. Br J Cancer 1996; 74: 128-132.
21. Argiris A, Li Y, Forastiere A,. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101: 2222-2229.
22. Kowalski LP, Carvalho AL,. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36: 1032-1037.
23. Shuman AG, Yang Y, Taylor JM, Prince ME,. End-of-life care among head and neck cancer patients. Otolaryngol Head Neck Surg 2011; 144: 733-739.
24. Davidson J, Keane T, Brown D, et al. Surgical salvage after radiotherapy for advanced laryngopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997; 123: 420-424.
25. Pivot X, Niyikiza C, Poissonnet G, et al. Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology 2001; 61: 197-204.
26. Stell PM,. Time to recurrence of squamous cell carcinoma of the head and neck. Head Neck 1991; 13: 277-281.
27. Liao CT, Chang JT, Wang HM, et al. Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: how and when? Cancer 2008; 112: 94-103.
28. Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 2009; 115: 5723-5733.
29. Choe KS, Haraf DJ, Solanki A, et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 2011; 117: 4671-4678.
30. Ganly I, Patel S, Matsuo J, et al. Postoperative complications of salvage total laryngectomy. Cancer 2005; 103: 2073-2081.
31. Lim JY, Lim YC, Kim SH, Byeon HK, Choi EC,. Factors predictive of successful outcome following salvage treatment of isolated neck recurrences. Otolaryngol Head Neck Surg 2010; 142: 832-837.
32. Ganly I, Patel SG, Matsuo J, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg 2006; 132: 59-66.
33. Sinclair CF, Rosenthal EL, McColloch NL, et al. Primary versus delayed tracheoesophageal puncture for laryngopharyngectomy with free flap reconstruction. Laryngoscope 2011; 121: 1436-1440.
34. Emerick KS, Tomycz L, Bradford CR, et al. Primary versus secondary tracheoesophageal puncture in salvage total laryngectomy following chemoradiation. Otolaryngol Head Neck Surg 2009; 140: 386-390.
35. Fu KK, Lichter A, Galante M,. Carcinoma of the floor of mouth: an analysis of treatment results and the sites and causes of failures. Int J Radiat Oncol Biol Phys 1976; 1: 829-837.
36. Mucke T, Wagenpfeil S, Kesting MR, Holzle F, Wolff KD,. Recurrence interval affects survival after local relapse of oral cancer. Oral Oncol 2009; 45: 687-691.
37. Liu SA, Wong YK, Lin JC, Poon CK, Tung KC, Tsai WC,. Impact of recurrence interval on survival of oral cavity squamous cell carcinoma patients after local relapse. Otolaryngol Head Neck Surg 2007; 136: 112-118.
38. Garofalo MC, Haraf DJ,. Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancer. Curr Opin Oncol 2002; 14: 330-333.
39. Netscher DT, Meade RA, Goodman CM, Alford EL, Stewart MG,. Quality of life and disease-specific functional status following microvascular reconstruction for advanced (T3 and T4) oropharyngeal cancers. Plast Reconstr Surg 2000; 105: 1628-1634.
40. Arce K, Bell RB, Potter JK, Buehler MJ, Potter BE, Dierks EJ,. Vascularized free tissue transfer for reconstruction of ablative defects in oral and oropharyngeal cancer patients undergoing salvage surgery following concomitant chemoradiation. Int J Oral Maxillofac Surg 2012; 41: 733-738.
41. Kostrzewa JP, Lancaster WP, Iseli TA, Desmond RA, Carroll WR, Rosenthal EL,. Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope 2010; 120: 267-272.
42. Taki S, Homma A, Oridate N, et al. Salvage surgery for local recurrence after chemoradiotherapy or radiotherapy in hypopharyngeal cancer patients. Eur Arch Otorhinolaryngol 2010; 267: 1765-1769.
43. Clark JR, de Almeida J, Gilbert R, et al. Primary and salvage (hypo)pharyngectomy: analysis and outcome. Head Neck 2006; 28: 671-677.
44. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ,. Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol 2004; 14: 190-195.
45. Virtaniemi JA, Kumpulainen EJ, Hirvikoski PP, Johansson RT, Kosma VM,. The incidence and etiology of postlaryngectomy pharyngocutaneous fistulae. Head Neck 2001; 23: 29-33.
46. Gleich LL, Ryzenman J, Gluckman JL, Wilson KM, Barrett WL, Redmond KP,. Recurrent advanced (T3 or T4) head and neck squamous cell carcinoma: is salvage possible? Arch Otolaryngol Head Neck Surg 2004; 130: 35-38.
47. Kadota HH, Fukushima JJ, Nakashima T, et al. Comparison of salvage and planned pharyngolaryngectomy with jejunal transfer for hypopharyngeal carcinoma after chemoradiotherapy. Laryngoscope 2010; 120: 1103-1108.
48. Miyamoto S, Sakuraba M, Nagamatsu S, Hayashi R,. Salvage total pharyngolaryngectomy and free jejunum transfer. Laryngoscope 2011; 121: 947-951.
49. Deschamps DR, Spencer HJ, Kokoska MS, Spring PM, Vural EA, Stack BC Jr,. Implications of head and neck cancer treatment failure in the neck. Otolaryngol Head Neck Surg 2010; 142: 722-727.
50. Wong LY, Wei WI, Lam LK, Yuen AP,. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003; 25: 953-959.
51. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007; 25: 4800-4805.
52. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008; 30: 281-288.
53. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998; 16: 3556-3562.
54. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA,. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 80: 669-676.
55. Mendenhall WM, Mendenhall CM, Malyapa RS, Palta JR, Mendenhall NP,. Re-irradiation of head and neck carcinoma. Am J Clin Oncol 2008; 31: 393-398.
56. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009; 73: 399-409.
57. Sher DJ, Haddad RI, Norris CM Jr, et al. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 2010; 116: 4761-4768.
58. Chen AM, Phillips TL, Lee NY,. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys 2011; 81: 1211-1219.
59. Watkins JM, Shirai KS, Wahlquist AE, et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck 2009; 31: 493-502.
60. Nieder C, Milas L, Ang KK,. Tissue tolerance to reirradiation. Semin Radiat Oncol 2000; 10: 200-209.
61. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-289.
62. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
63. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
64. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-526.
65. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
66. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19: 1088-1095.
67. Mohide EA, Archibald SD, Tew M, Young JE, Haines T,. Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals. Am J Surg 1992; 164: 619-622.